Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience

J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e144-e145. doi: 10.1111/jdv.15367. Epub 2018 Dec 17.

Authors

N Woltsche¹, N Pichler², I Wolf², N Di Meo³, I Zalaudek³

Affiliations

¹ Department of Ophthalmology, Medical University of Graz, Graz, Austria.
² Department of Dermatology & Venereology, Medical University of Graz, Graz, Austria.
³ Dermatology Clinic, University of Trieste, Trieste, Italy.

PMID: 30472793
DOI: 10.1111/jdv.15367

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Anilides / administration & dosage*
Anilides / adverse effects
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects
Carcinoma, Basal Cell / drug therapy*
Female
Hedgehog Proteins / antagonists & inhibitors
Humans
Male
Middle Aged
Pyridines / administration & dosage*
Pyridines / adverse effects
Retrospective Studies
Skin Neoplasms / drug therapy*

Substances

Anilides
Antineoplastic Agents
Hedgehog Proteins
HhAntag691
Pyridines